Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Here we go again: Forest picks up Icahn's gauntlet and does battle

This article was originally published in Scrip

Executive Summary

We've seen it before and we'll probably see it again: a biotech or pharma company gets into a sticky patch, and before they know it activist investor Carl Icahn has bought up a chunk of shares and is demanding they wash their dirty laundry under the watchful eyes of his "independent" directors. This time it's Forest Laboratories' turn to vigorously repel Mr Icahn's advances.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts